Neurelis, Inc. ("Company"), today announced a transaction with OrbiMed for the sale of the Company's rights, royalty ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good day, and welcome to the ARS Pharmaceuticals Third Quarter ...

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak ...

Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand ...

ALK-Abelló has acquired rights to Neffy adrenaline nasal spray in Europe and Canada, amongst other countries, from ARS ...

Commercial launch of neffy®(epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by ...

ARS Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing solutions for patients with allergic reactions, particularly anaphylaxis, through innovative products like their ...

The agreement grants ALK exclusive global rights to the neffy adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key ...

In a pivotal development this year, the U.S. Food and Drug Administration approved neffy (epinephrine nasal spray) in August 2024 for emergency use in type 1 allergic reactions, such as anaphylaxis.

The Adrenaverse platform is a relatively new platform by Aquestive. This platform is essentially the 'secret-sauce' ...

We are convinced that neffy® will transform anaphylaxis, benefitting patients at risk and leading to a significant expansion of the market.” Exclusive rights to new indications ARS Pharma is ...